[HTML][HTML] PCSK9 inhibition: from current advances to evolving future
C Liu, J Chen, H Chen, T Zhang, D He, Q Luo, J Chi… - Cells, 2022 - mdpi.com
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secretory serine protease
synthesized primarily by the liver. It mainly promotes the degradation of low-density …
synthesized primarily by the liver. It mainly promotes the degradation of low-density …
Mouse models of atherosclerosis in translational research
Atherosclerotic cardiovascular disease (CVD), the major cause of premature human
mortality, is a chronic and progressive metabolic and inflammatory disease in large-and …
mortality, is a chronic and progressive metabolic and inflammatory disease in large-and …
Lipid-laden foam cells in the pathology of atherosclerosis: shedding light on new therapeutic targets
Introduction Lipid-laden foam cells within atherosclerotic plaques are key players in all
phases of lesion development including its progression, necrotic core formation, fibrous cap …
phases of lesion development including its progression, necrotic core formation, fibrous cap …
[HTML][HTML] Lipid oxidation in pathophysiology of atherosclerosis: Current understanding and therapeutic strategies
A marked increase in the global prevalence of ischemic heart disease demands focused
research for novel and more effective therapeutic strategies. At present, atherosclerotic …
research for novel and more effective therapeutic strategies. At present, atherosclerotic …
PCSK9 and atherosclerosis: Looking beyond LDL regulation
Abstract Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) is involved in cholesterol
homeostasis. After binding to the complex low‐density lipoprotein (LDL)‐receptor, PCSK9 …
homeostasis. After binding to the complex low‐density lipoprotein (LDL)‐receptor, PCSK9 …
The role of PCSK9 in heart failure and other cardiovascular diseases—mechanisms of action beyond its effect on LDL cholesterol
Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a protein that regulates low-density
lipoprotein (LDL) cholesterol metabolism by binding to the hepatic LDL receptor (LDLR) …
lipoprotein (LDL) cholesterol metabolism by binding to the hepatic LDL receptor (LDLR) …
PCSK9 functions in atherosclerosis are not limited to plasmatic LDL-cholesterol regulation
A Luquero, L Badimon, M Borrell-Pages - Frontiers in cardiovascular …, 2021 - frontiersin.org
The relevance of PCSK9 in atherosclerosis progression is demonstrated by the benefits
observed in patients that have followed PCSK9-targeted therapies. The impact of these …
observed in patients that have followed PCSK9-targeted therapies. The impact of these …
Quercetin alleviates atherosclerosis by suppressing oxidized LDL-induced senescence in plaque macrophage via inhibiting the p38MAPK/p16 pathway
G Luo, L **ang, L **ao - The Journal of Nutritional Biochemistry, 2023 - Elsevier
Quercetin is a widely known and biologically active phytochemical and exerts therapeutic
effects against atherosclerosis. The removal of senescent plaque macrophages effectively …
effects against atherosclerosis. The removal of senescent plaque macrophages effectively …
[HTML][HTML] Insight into the Evolving Role of PCSK9
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is the last discovered member of the
family of proprotein convertases (PCs), mainly synthetized in hepatic cells. This serine …
family of proprotein convertases (PCs), mainly synthetized in hepatic cells. This serine …
Sex difference in circulating PCSK9 and its clinical implications
F Jia, SF Fei, DB Tong, C Xue, JJ Li - Frontiers in pharmacology, 2022 - frontiersin.org
Proprotein convertase subtilisin kexin type 9 (PCSK9) is a proprotein convertase that
increases plasma low-density lipoprotein cholesterol (LDL-C) levels by triggering the …
increases plasma low-density lipoprotein cholesterol (LDL-C) levels by triggering the …